Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05845307
Other study ID # 2022-0001
Secondary ID NCI-2023-03573
Status Not yet recruiting
Phase Early Phase 1
First received
Last updated
Start date October 31, 2024
Est. completion date February 1, 2025

Study information

Verified date May 2024
Source M.D. Anderson Cancer Center
Contact Andrew Sikora, MD,PHD
Phone (646) 656-0125
Email agsikora@mdanderson.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To learn if TTI-101 can reduce the growth of HPV-negative squamous cell carcinomas of the head and neck when given before standard of care surgery.


Description:

Objectives: Primary: • To determine the change in pY-STAT3 H-score in tumor tissue in post-treatment resection specimens versus pre-treatment biopsy specimens. Secondary: - To determine the safety and tolerability of pre-surgery TTI-101 in patients with Stage II-IV HPV-negative HNSCC who are planned for definitive local surgery with or without radiation. - To determine the individual pre/post treatment changes in pY-STAT3 H-scores in epithelial and stromal tumor cells. - To determine the pathologic response rate to pre-surgery TTI-101. - To determine the overall response rate (ORR) to pre-surgery TTI-101 using RECIST v1.1 criteria. - To determine the disease free, disease specific and overall survival (DFS, DSS, OS) after pre-surgery TTI-101 treatment and SOC surgery. Exploratory: - To evaluate the effects of pre-surgery TTI-101 on circulating and tumor-infiltrating immunocytes, and on the intratumoral expression of PD-1 along with other immune related molecules. - To compare outcome measures (response rate and survival) in control versus TTI-101-treated patients. - To determine the association of immunologic changes with treatment response. - To determine the association of pharmacokinetic (PK) measures with treatment response.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 33
Est. completion date February 1, 2025
Est. primary completion date February 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Patients must meet the following criteria for study entry: - Biopsy-proven primary Stage II-IV squamous cell carcinoma of the head and neck - For oropharyngeal cancer patients: HPV-negative by p16 and/or direct high-risk HPV assessment - Surgical resection must be planned as primary therapy with or without adjuvant radiation therapy. - Signed Informed Consent Form (ICF). - Ability and willingness to comply with the requirements of the study protocol. - Ability to swallow study drug. - Age years of 18 years. - Measurable disease per RECIST v1.1 (see Appendix 2) and/or per direct clinical measurements. - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 (see Appendix 4) - Adequate hematologic and hepatorenal function, defined by the following laboratory results obtained within 4 weeks prior to study entry: - ANC 1500 cells/L - Platelet count 100,000/L; - Hemoglobin 9.0 g/dL - Total bilirubin 1.5 upper limit of normal (ULN) with the following exception: Patients with known Gilbert disease who have serum bilirubin level 3 ULN may be enrolled. - AST and ALT 2.5 ULN - Alkaline phosphatase 2.5 ULN - Serum creatinine clearance =60 mL/min, measured or calculated per institutional standard protocol • INR and aPTT 1.5 ULN - This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation (such as low-molecular-weight heparin or warfarin) should be on a stable dose. - No evidence of distant metastases. - A male participant must agree to use contraception as detailed in Appendix 3 of this protocol during the treatment period and for at least 90 days after the last dose of study treatment and refrain from donating sperm during this period. - A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: - Not a woman of childbearing potential (WOCBP) as defined in Appendix 3 OR - A WOCBP who agrees to follow the contraceptive guidance in Appendix 3 during the treatment period and for at least 90 days after the last dose of study treatment. Exclusion Criteria: Patients who meet any of the following criteria will be excluded from study entry. General Exclusion Criteria: - Any prior systemic or radiotherapy within the last 4 months directed towards the squamous cell carcinoma of the head and neck that is to be resected as part of SOC therapy. - Standard of care anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, for concurrent malignancy or unresected squamous cell carcinoma of the head and neck within 3 weeks prior to initiation of study treatment. - AEs from prior anticancer therapy that have not resolved to Grade 1 except for alopecia, Grade 2 neuropathy or endocrine-related AEs Grade =2 requiring treatment or hormone replacement are eligible - Pregnancy, lactation, or breastfeeding - Inability to comply with study and follow-up procedures - Has a known active Hepatitis B (defined as Hepatitis B RNA detected) or known active Hepatitis C virus (defined as HCV RNA is detected) infection, or known active HIV (defined as HIV RNA is detected) infection. - Active tuberculosis - Severe infections within 4 weeks prior to treatment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia - Signs or symptoms of infection as determined by the treating team within 2 weeks prior to treatment - Major surgical procedure within 28 days prior to treatment - Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed or mRNA vaccines is allowed. - Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, well-differentiated thyroid cancer, or carcinoma in situ that have undergone potentially curative therapy are not excluded. - History of significantly impaired cardiac function such as unstable angina pectoris, congestive heart failure with New York Heart Association (NYHA) class III or IV, myocardial infarction within the last 12 months prior to trial entry; signs of pericardial effusion, serious arrhythmia (including QTc prolongation of >470 ms and/or pacemaker) or prior diagnosis of congenital long QT syndrome or left ventricular ejection fraction <50% on echocardiogram. - History of cerebral vascular accident or stroke within the previous 2 years. - Uncontrolled hypertension (>160/100mm Hg). - History of Grade 3 or 4 allergic reactions attributed to compounds of similar chemicalor biologic composition as TTI-101 (hydroxyl-naphthalene sulfonamides). - Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation - Previous treatment of the current malignancy with a STAT inhibitor. - Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications Medication-Related Exclusion Criteria: - Bisphosphonate therapy for symptomatic hypercalcemia - Use of bisphosphonate therapy for other reasons (e.g., osteoporosis) is allowed. - Received oral or IV antibiotics within 2 weeks prior to treatment - Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible. - Treatment with an investigational agent (not standard of care) within 3 weeks prior to treatment (or within five halflives of the investigational product, whichever is longer) - Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to treatment - Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled. - The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Control Group
Given by PO
TTI-101
Given by PO

Locations

Country Name City State
United States M D Anderson Cancer Centerl Houston Texas

Sponsors (3)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center National Institutes of Health (NIH), Tvardi Therapeutics, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 through study completion; an average of 1 year.
See also
  Status Clinical Trial Phase
Completed NCT04879849 - A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers Phase 1
Active, not recruiting NCT04474470 - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Phase 1/Phase 2
Completed NCT02537223 - Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer Phase 1
Completed NCT00824343 - A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer Phase 2
Recruiting NCT06022757 - Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) Phase 1/Phase 2
Recruiting NCT05366166 - Pembrolizumab Plus Olaparib in LA-HNSCC Phase 2
Terminated NCT04502888 - Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin Phase 1
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Completed NCT04098458 - Navigation for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC N/A
Not yet recruiting NCT04528420 - Optimised Early Management of Squamous Cell Carcinoma of the Head and Neck Cancer N/A
Active, not recruiting NCT03997968 - A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05061420 - A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204) Phase 2
Completed NCT04939480 - Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN Phase 2
Recruiting NCT04260802 - A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Phase 1/Phase 2
Recruiting NCT04465487 - Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies Phase 1
Active, not recruiting NCT04489888 - A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10) Phase 4
Recruiting NCT05544929 - A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers Phase 1
Completed NCT04601402 - GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy Phase 1
Completed NCT00756444 - A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck Phase 2
Withdrawn NCT04129320 - Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck Phase 2/Phase 3

External Links